CervoMed Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
CRVO
- Investments
-
1
- Share Price
-
$1.69
- (As of Friday Closing)
CervoMed General Information
Description
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Contact Information
Website
www.cervomed.comCorporate Office
- 20 Park Plaza
- Suite 424
- Boston, MA 02116
- United States
Corporate Office
- 20 Park Plaza
- Suite 424
- Boston, MA 02116
- United States
CervoMed Timeline
CervoMed Stock Performance
As of 13-Nov-2026, CervoMed’s stock price is $1.69. Its current market cap is $25.6M with 15.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.69 | $1.83 | $1.27 - $10.00 | $25.6M | 15.1M | 482K | -$2.65 |
CervoMed Financials Summary
As of 30-Sep-2026, CervoMed has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 19,966 | 45,802 | (27,343) | 32,872 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (29,222) | (28,303) | (18,228) | (2,391) |
| Net Income | (28,519) | (26,966) | (16,291) | (2,172) |
| Total Assets | 21,330 | 22,879 | 43,082 | 9,973 |
| Total Debt | 0 | 0 | 0 | 0 |
CervoMed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CervoMed Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
CervoMed Comparisons
Industry
Financing
Details
CervoMed Competitors (23)
One of CervoMed’s 23 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Asceneuron | Venture Capital-Backed | Eysins, Switzerland | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA |
CervoMed Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CervoMed Patents
CervoMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026128463-A1 | Neflamapimod for use in methods of treating aphasia | Pending | 09-Dec-2024 | ||
| AU-2022380947-A1 | Treatment of a selective population of patients having dementia with lewy bodies | Pending | 05-Nov-2021 | ||
| CA-3234513-A1 | Treatment of a selective population of patients having dementia with lewy bodies | Pending | 05-Nov-2021 | ||
| EP-4426309-A1 | Treatment of a selective population of patients having dementia with lewy bodies | Pending | 05-Nov-2021 | ||
| EP-4426309-A4 | Treatment of a selective population of patients having dementia with lewy bodies | Pending | 05-Nov-2021 | A61K31/519 |
CervoMed Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CervoMed Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CervoMed Acquisitions (1)
CervoMed’s most recent deal was a Merger/Acquisition with Diffusion Pharmaceuticals. The deal was made on 16-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Diffusion Pharmaceuticals | 16-Aug-2023 | Merger/Acquisition | Drug Discovery |
CervoMed ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
CervoMed FAQs
-
When was CervoMed founded?
CervoMed was founded in 2014.
-
Where is CervoMed headquartered?
CervoMed is headquartered in Boston, MA.
-
What is the size of CervoMed?
CervoMed has 15 total employees.
-
What industry is CervoMed in?
CervoMed’s primary industry is Drug Discovery.
-
Is CervoMed a private or public company?
CervoMed is a Public company.
-
What is CervoMed’s stock symbol?
The ticker symbol for CervoMed is CRVO.
-
What is the current stock price of CervoMed?
As of 13-Nov-2026 the stock price of CervoMed is $1.69.
-
What is the current market cap of CervoMed?
The current market capitalization of CervoMed is $25.6M.
-
Who are CervoMed’s competitors?
NeuroNascent, Asceneuron, Cognition Therapeutics, Alzheon, and Minerva Neurosciences are some of the 23 competitors of CervoMed.
-
What is CervoMed’s annual earnings per share (EPS)?
CervoMed’s EPS for 12 months was -$2.65.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
